Cellect Biotechnology Ltd. , a developer of stem cells selection technology, today announces that it has treated the first blood cancer patient in the recently initiated Phase I/II trial of its stem cell technology ApoGraftTM. The trial is intended to assess the Cellect ApoGraftTM process which is designed to prevent Graft-versus-Host Disease , a common complication associated with stem cell transplant in which the transplanted immune cells attack the recipient’s body cells and organs.